TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents
Brief Summary: The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.


Options:
A: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM
B: Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: behavior therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voucher-based contingency management; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
D: Arm Label: ICC; Type: EXPERIMENTAL; Interventions: Other: Integrated collaborative care | Arm Label: E&R; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and Resources | Intervention Type: OTHER; Name: Integrated collaborative care; Assigned to Arm(s): ICC | Intervention Type: OTHER; Name: Education and Resources; Assigned to Arm(s): E&R

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents
Brief Summary: The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic-based substance abuse treatment with buprenorphine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Case management and referred substance abuse treatment | Intervention Type: BEHAVIORAL; Name: Clinic-based substance abuse treatment with buprenorphine; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Case management and referred substance abuse treatment; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
C: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine/naloxone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents
Brief Summary: The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.


Options:
A: Arm Label: 1-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 2-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 4-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: buprenorphine taper followed by naltrexone maintenance; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper
B: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
C: Arm Label: Probuphine; Type: EXPERIMENTAL; Interventions: Drug: Probuphine (buprenorphine implant) | Arm Label: placebo implant; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo implant | Arm Label: sublingual buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Probuphine (buprenorphine implant); Assigned to Arm(s): Probuphine | Intervention Type: DRUG; Name: placebo implant; Assigned to Arm(s): placebo implant | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): sublingual buprenorphine
D: Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents
Brief Summary: The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.


Options:
A: Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
C: Arm Label: Sequence 1: Placebo, Combo, Palonosetron; Type: EXPERIMENTAL; Interventions: Drug: Palonosetron, Drug: Hydroxyzine, Other: Placebo | Arm Label: Sequence 2: Palonosetron, Combo, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Palonosetron, Drug: Hydroxyzine, Other: Placebo | Arm Label: Sequence 3: Combo, Placebo, Palonosetron; Type: EXPERIMENTAL; Interventions: Drug: Palonosetron, Drug: Hydroxyzine, Other: Placebo | Arm Label: Sequence 4: Placebo, Palonosetron, Combo; Type: EXPERIMENTAL; Interventions: Drug: Palonosetron, Drug: Hydroxyzine, Other: Placebo | Arm Label: Sequence 5: Combo, Palonosetron, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Palonosetron, Drug: Hydroxyzine, Other: Placebo | Arm Label: Sequence 6: Palonosetron, Placebo, Combo; Type: EXPERIMENTAL; Interventions: Drug: Palonosetron, Drug: Hydroxyzine, Other: Placebo | Intervention Type: DRUG; Name: Palonosetron; Assigned to Arm(s): Sequence 1: Placebo, Combo, Palonosetron, Sequence 2: Palonosetron, Combo, Placebo, Sequence 3: Combo, Placebo, Palonosetron, Sequence 4: Placebo, Palonosetron, Combo, Sequence 5: Combo, Palonosetron, Placebo, Sequence 6: Palonosetron, Placebo, Combo | Intervention Type: DRUG; Name: Hydroxyzine; Assigned to Arm(s): Sequence 1: Placebo, Combo, Palonosetron, Sequence 2: Palonosetron, Combo, Placebo, Sequence 3: Combo, Placebo, Palonosetron, Sequence 4: Placebo, Palonosetron, Combo, Sequence 5: Combo, Palonosetron, Placebo, Sequence 6: Palonosetron, Placebo, Combo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Sequence 1: Placebo, Combo, Palonosetron, Sequence 2: Palonosetron, Combo, Placebo, Sequence 3: Combo, Placebo, Palonosetron, Sequence 4: Placebo, Palonosetron, Combo, Sequence 5: Combo, Palonosetron, Placebo, Sequence 6: Palonosetron, Placebo, Combo
D: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents
Brief Summary: The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.


Options:
A: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Peer Education Intervention; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Motivational Enhancement Therapy (MET) to Improve Treatment Utilization in Pregnant Substance Users
Brief Summary: The purpose of this study is to compare Motivational Enhancement Therapy (MET) with standard drug abuse treatment among pregnant women.


Options:
A: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
B: Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: usual care | Arm Label: CHAT brief MI intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CHAT brief MI intervention | Intervention Type: BEHAVIORAL; Name: CHAT brief MI intervention; Assigned to Arm(s): CHAT brief MI intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): Usual Care
C: Arm Label: Motivational Enhancement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy (MET) | Arm Label: Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health education | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy (MET); Assigned to Arm(s): Motivational Enhancement Therapy | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Health Education
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Brief motivational intervention | Intervention Type: BEHAVIORAL; Name: Brief motivational intervention; Assigned to Arm(s): Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Treatment for Trauma and Substance Use Disorders
Brief Summary: The purpose of this study is to compare the effectiveness of adding Seeking Safety to standard substance abuse treatment to adding a control condition: Women's Health Education to standard substance abuse treatment.


Options:
A: Arm Label: Treatment As Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Enhancement Therapy (MET); Type: EXPERIMENTAL; Interventions: Behavioral: Motivation Enhancement Therapy (MET) | Arm Label: Peer-delivered Twelve Step Facilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-Twelve Step Facilitation (P-TSF) | Intervention Type: BEHAVIORAL; Name: Motivation Enhancement Therapy (MET); Assigned to Arm(s): Motivational Enhancement Therapy (MET) | Intervention Type: BEHAVIORAL; Name: Peer-Twelve Step Facilitation (P-TSF); Assigned to Arm(s): Peer-delivered Twelve Step Facilitation
B: Arm Label: Network Support; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Packaged Cognitive-Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Network Support, Packaged Cognitive-Behavioral Treatment
C: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
D: Arm Label: Introduction to AA volunteer; Type: OTHER; Interventions: Other: Introduction to AA volunteer | Arm Label: AA materials offered; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Introduction to AA volunteer; Assigned to Arm(s): Introduction to AA volunteer

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Treatment for Trauma and Substance Use Disorders
Brief Summary: The purpose of this study is to compare the effectiveness of adding Seeking Safety to standard substance abuse treatment to adding a control condition: Women's Health Education to standard substance abuse treatment.


Options:
A: Arm Label: Strength at Home Couples Group; Type: EXPERIMENTAL; Interventions: Behavioral: Strength at Home Couples Group | Arm Label: Supportive Group Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Group Therapy | Intervention Type: BEHAVIORAL; Name: Strength at Home Couples Group; Assigned to Arm(s): Strength at Home Couples Group | Intervention Type: BEHAVIORAL; Name: Supportive Group Therapy; Assigned to Arm(s): Supportive Group Therapy
B: Arm Label: Internet Based Safety Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based safety decision aid | Arm Label: Control Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Safety Plan | Intervention Type: BEHAVIORAL; Name: Internet-based safety decision aid; Assigned to Arm(s): Internet Based Safety Decision Aid | Intervention Type: BEHAVIORAL; Name: Usual Care Safety Plan; Assigned to Arm(s): Control Website
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Public Health Nurse Home Visit | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intimate Partner Violence (IPV) Protocol | Intervention Type: BEHAVIORAL; Name: Public Health Nurse Home Visit; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Intimate Partner Violence (IPV) Protocol; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Treatment for Trauma and Substance Use Disorders
Brief Summary: The purpose of this study is to compare the effectiveness of adding Seeking Safety to standard substance abuse treatment to adding a control condition: Women's Health Education to standard substance abuse treatment.


Options:
A: Arm Label: Seeking Safety; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Modified Seeking Safety integrated into std outpatient SUD care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard outpatient SUD care | Intervention Type: BEHAVIORAL; Name: Modified Seeking Safety integrated into std outpatient SUD care; Assigned to Arm(s): Seeking Safety | Intervention Type: BEHAVIORAL; Name: Standard outpatient SUD care; Assigned to Arm(s): Usual Care
B: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Individual Addiction Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual Addiction Counseling | Arm Label: Treatment-as-usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment-as-usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Individual Addiction Counseling; Assigned to Arm(s): Individual Addiction Counseling | Intervention Type: BEHAVIORAL; Name: Treatment-as-usual; Assigned to Arm(s): Treatment-as-usual
C: Arm Label: Naltrexone alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: Naltrexone with CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-Behavioral Therapy, Drug: Naltrexone | Arm Label: Placebo with CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Placebo alone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Naltrexone with CBT for PTSD, Placebo with CBT for PTSD | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone alone, Naltrexone with CBT for PTSD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo alone
D: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Treatment for Trauma and Substance Use Disorders
Brief Summary: The purpose of this study is to compare the effectiveness of adding Seeking Safety to standard substance abuse treatment to adding a control condition: Women's Health Education to standard substance abuse treatment.


Options:
A: Arm Label: CBT-E; Type: EXPERIMENTAL; Interventions: Behavioral: Specific Modules, Behavioral: Cognitive behavioral therapy | Arm Label: CBT-C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy | Intervention Type: BEHAVIORAL; Name: Specific Modules; Assigned to Arm(s): CBT-E | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): CBT-C, CBT-E
B: Arm Label: Qigong training; Type: EXPERIMENTAL; Interventions: Behavioral: Qigong training | Arm Label: Wait-list control- Health talks; Type: OTHER; Interventions: Other: Wait-list control- Health talks | Intervention Type: BEHAVIORAL; Name: Qigong training; Assigned to Arm(s): Qigong training | Intervention Type: OTHER; Name: Wait-list control- Health talks; Assigned to Arm(s): Wait-list control- Health talks
C: Arm Label: ROSE Program; Type: EXPERIMENTAL; Interventions: Behavioral: ROSE Program | Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ROSE Program; Assigned to Arm(s): ROSE Program
D: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1
C: Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
D: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.


Options:
A: Arm Label: IFNB-1b 500 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg*; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 500 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg*
B: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3
D: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®

Answer: D